Evidence map›Paper›PMID 41249101›Full record

ReviewRenal failure2025

Biological targeted therapy for lupus nephritis-the role of BLYS and APRIL.

Xin Yang, Siyi Liu, Xiu-Juan Liu, Dan Wen, Yan Zhou, Ying Zeng, Longzhu Li, Qing Deng, Yu Wang, Qinkai Chen and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xin YangDepartment of Nephrology, the First Affiliated Hospital of Nanchang University, Nanchang, Institute of molecular immunology for kidney disease of Nanchang University, Nanchang City, Jiangxi, China.
Siyi LiuDepartment of Nephrology, the First Affiliated Hospital of Nanchang University, Nanchang, Institute of molecular immunology for kidney disease of Nanchang University, Nanchang City, Jiangxi, China.
Xiu-Juan LiuDepartment of Nephrology, the 908th Hospital of the People's Liberation Army Joint Logistics Support Force, The Great Wall Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi, China.
Dan WenDepartment of Nephrology, the First Affiliated Hospital of Nanchang University, Nanchang, Institute of molecular immunology for kidney disease of Nanchang University, Nanchang City, Jiangxi, China.
Yan ZhouDepartment of Nephrology, the First Affiliated Hospital of Nanchang University, Nanchang, Institute of molecular immunology for kidney disease of Nanchang University, Nanchang City, Jiangxi, China.
Ying ZengDepartment of Nephrology, the First Affiliated Hospital of Nanchang University, Nanchang, Institute of molecular immunology for kidney disease of Nanchang University, Nanchang City, Jiangxi, China.
Longzhu LiDepartment of Nephrology, the First Affiliated Hospital of Nanchang University, Nanchang, Institute of molecular immunology for kidney disease of Nanchang University, Nanchang City, Jiangxi, China.
Qing DengDepartment of Nephrology, the First Affiliated Hospital of Nanchang University, Nanchang, Institute of molecular immunology for kidney disease of Nanchang University, Nanchang City, Jiangxi, China.
Yu WangDepartment of Nephrology, the First Affiliated Hospital of Nanchang University, Nanchang, Institute of molecular immunology for kidney disease of Nanchang University, Nanchang City, Jiangxi, China.
Qinkai ChenDepartment of Nephrology, the First Affiliated Hospital of Nanchang University, Nanchang, Institute of molecular immunology for kidney disease of Nanchang University, Nanchang City, Jiangxi, China.
Jinlei LvDepartment of Nephrology, the First Affiliated Hospital of Nanchang University, Nanchang, Institute of molecular immunology for kidney disease of Nanchang University, Nanchang City, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lupus nephritis (LN) is a frequent and serious complication of systemic lupus erythemosus (SLE). Both innate and adaptive immunity play essential roles in the initiation and progression of LN. B-lymphocyte stimulator (BLYS) and a proliferation-inducing ligand (APRIL), members of the tumor necrosis factor superfamily, bind to receptors such as B-cell activating factor receptor 3 (BR3), transmembrane activator and CAML interactor protein (TACI), and B-cell maturation antigen (BCMA). BLYS and APRIL are often overexpressed in LN, showing a positive correlation with disease activity. Therapeutic targeting of BLYS/APRIL has demonstrated efficacy in reducing LN activity. Traditional immunosuppressants often have multiple contraindications and side effects due to their broad immune-suppressing effects. Recently, B-cell-targeting agents, including rituximab, belimumab, as well as telitacicept have shown promising efficacy and reduced side effects in LN treatment. Telitacicept, a novel biological agent, has been approved firstly effective for SLE treatment in China. This review focus on the role of BLYS and APRIL in LN development and progression, alongside clinical data on the targeted therapies of above biologicals.

Indexed as

B-Cell Activating FactorLupus NephritisTumor Necrosis Factor Ligand Superfamily Member 13Antibodies, Monoclonal, HumanizedB-LymphocytesHumansImmunosuppressive AgentsMolecular Targeted TherapyRecombinant Fusion ProteinsRituximabAntibodies, Monoclonal, HumanizedB-Cell Activating FactorbelimumabImmunosuppressive AgentsRecombinant Fusion ProteinsRituximabTNFSF13B protein, humanTNFSF13 protein, humanTumor Necrosis Factor Ligand Superfamily Member 13a proliferation-inducing ligand APRILB-cell activating factor BAFFlupus nephritissystemic lupus erythematosustelitacicept

Identifiers

PMID41249101
PMCPMC12624907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.